BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T, Mascarenhas J. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 2020;4:655-66. [PMID: 32078681 DOI: 10.1182/bloodadvances.2019001310] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Alkassis S, Zaher N, Kaloti Z, Levine D. Idiopathic portal vein thrombosis not related to hepatic disease or malignancy. BMJ Case Rep 2021;14:e245620. [PMID: 34753728 DOI: 10.1136/bcr-2021-245620] [Reference Citation Analysis]
2 Ju C, Li X, Gadani S, Kapoor B, Partovi S. Portal Vein Thrombosis: Diagnosis and Endovascular Management. Rofo 2021. [PMID: 34649289 DOI: 10.1055/a-1642-0990] [Reference Citation Analysis]
3 Mathew C, Zumberg M. Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins? Hematology Am Soc Hematol Educ Program 2021;2021:100-5. [PMID: 34889369 DOI: 10.1182/hematology.2021000319] [Reference Citation Analysis]
4 Kirkeby MH, Larsen JB, Grønbaek H, Hvas AM. Thrombophilia testing in patients with portal vein thrombosis. Scand J Clin Lab Invest 2020;80:694-8. [PMID: 33026843 DOI: 10.1080/00365513.2020.1827289] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Naymagon L, Tremblay D, Mascarenhas J, Schiano T. Characteristics, anticoagulation, and outcomes of portal vein thrombosis after intra-abdominal surgery. Surgery 2021;169:1175-81. [PMID: 33358635 DOI: 10.1016/j.surg.2020.11.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wang L, Guo X, Xu X, De Stefano V, Plessier A, Noronha Ferreira C, Qi X. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. Adv Ther 2021;38:495-520. [PMID: 33155180 DOI: 10.1007/s12325-020-01550-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kishore S, Khaja MS, Thornburg B, Sharma AM, Knuttinen MG, Shamoun F, Mantha S, Desai KR, Sista AK, Black SA, O'Sullivan GJ, Kaufman JA, Hofmann LV, Winokur RS. Antithrombotic Therapy After Venous Interventions: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2022. [PMID: 35352572 DOI: 10.2214/AJR.22.27413] [Reference Citation Analysis]
8 Riva N, Ageno W. Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. J Clin Med 2020;9:E743. [PMID: 32164214 DOI: 10.3390/jcm9030743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zheng SM, Lin N, Tang SH, Yang JY, Wang HQ, Luo SL, Zhang Y, Mu D. Isolated hepatic tuberculosis associated with portal vein thrombosis and hepatitis B virus coinfection: A case report and review of the literature. World J Clin Cases 2021; 9(30): 9310-9319 [PMID: 34786418 DOI: 10.12998/wjcc.v9.i30.9310] [Reference Citation Analysis]
10 Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. [PMID: 34217184 DOI: 10.51821/84.2.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Schafer AI. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2021;35:305-24. [PMID: 33641871 DOI: 10.1016/j.hoc.2020.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. [PMID: 33219529 DOI: 10.1002/hep.31646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
13 Naymagon L. Venous thrombosis of the liver: current and emerging concepts in management. Transl Res 2020;225:54-69. [PMID: 32407789 DOI: 10.1016/j.trsl.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Ai MH, Dong WG, Tan XP, Xu L, Xu C, Zhang Q, Zhang Y, Li J. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020;32:1395-400. [PMID: 32675774 DOI: 10.1097/MEG.0000000000001846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
15 Martens K, McMurry HS, Koprowski S, Hum J, Haraga J, Jou JH, Shatzel JJ. Anticoagulation in Cirrhosis: Evidence for the Treatment of Portal Vein Thrombosis and Applications for Prophylactic Therapy. J Clin Gastroenterol 2022. [PMID: 35537133 DOI: 10.1097/MCG.0000000000001713] [Reference Citation Analysis]
16 Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. DOACs and "newer" hemophilia therapies in COVID-19: Reply. J Thromb Haemost 2020;18:1795-6. [PMID: 32282993 DOI: 10.1111/jth.14841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
17 Riva N, Ageno W. Direct oral anticoagulants for unusual-site venous thromboembolism. Res Pract Thromb Haemost 2021;5:265-77. [PMID: 33733025 DOI: 10.1002/rth2.12480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Li H, Sun PM, Sun HW, Cui Y. Progress in clinical diagnosis and treatment of cavernous transformation of the portal vein. Shijie Huaren Xiaohua Zazhi 2021; 29(12): 662-669 [DOI: 10.11569/wcjd.v29.i12.662] [Reference Citation Analysis]
19 Tremblay D, Mascarenhas J, Schiano T, Naymagon L. Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". J Hepatol 2021;74:249-50. [PMID: 32981751 DOI: 10.1016/j.jhep.2020.07.044] [Reference Citation Analysis]
20 Riat R, Gomez K; British Society for Haematology Haemostasis and Thrombosis Taskforce. Addendum to guidelines on the investigation and management of venous thrombosis at unusual sites (Br. J. Haematol. 2012;159:28-38): Use of Direct Oral Anticoagulants. Br J Haematol 2022. [PMID: 35389508 DOI: 10.1111/bjh.18189] [Reference Citation Analysis]
21 Wu WY, Kong DR. Advances in diagnosis and treatment of portal venous thrombosis. Shijie Huaren Xiaohua Zazhi 2021; 29(4): 165-173 [DOI: 10.11569/wcjd.v29.i4.165] [Reference Citation Analysis]
22 Rupoli S, Fiorentini A, Morsia E, Svegliati-Baroni G, Micucci G, Maroni L, Garvey KB, Fiorentini A, Riva A, Da Lio L, Benedetti A, Offidani M, Olivieri A, Giuseppe T. Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. Vasc Health Risk Manag 2021;17:619-29. [PMID: 34594107 DOI: 10.2147/VHRM.S310615] [Reference Citation Analysis]
23 Riva N, Carrier M, Gatt A, Ageno W. Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. Res Pract Thromb Haemost 2020;4:1192-202. [PMID: 33134784 DOI: 10.1002/rth2.12424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Yao W, Feng Y, Liu T, Li W, Zhang M, Yao Y, Wu S. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial. EXCLI J 2021;20:537-49. [PMID: 33883982 DOI: 10.17179/excli2020-3120] [Reference Citation Analysis]
25 Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. Eur J Gastroenterol Hepatol 2021;33:911-6. [PMID: 33079786 DOI: 10.1097/MEG.0000000000001958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]